Chronic Kidney Disease Market: Global Industry Analysis and Forecast (2024-2030)

Chronic Kidney Disease Market Overview

Chronic Kidney Disease refers to the gradual loss of kidney function over time. As the disease advances, the kidneys become less efficient at removing waste and excess fluids from the body, leading to complications such as high blood pressure, anemia, and bone disease. About 10% of the adult population is living with some degree of CKD, and every year millions die prematurely from CKD and related complications. Chronic Kidney Disease is the third fastest-growing cause of death.

The In-depth research report on the Chronic Kidney Disease market provides a detailed analysis of market dynamics, trends, competitive landscape, and future outlook, aimed at informing stakeholders, healthcare providers, investors, and policymakers about the evolving landscape of CKD treatment and management. Chronic Kidney Disease (CKD) is emerging as a significant global health challenge, marked by alarming increases in prevalence and mortality rates. From 1990 to 2020, CKD-related deaths surged by 41.5%, elevating it from the 17th to the 10th leading cause of death worldwide.

Chronic Kidney Disease (CKD) prevalence is escalating globally, primarily due to the increasing rates of diabetes, hypertension, and obesity, which significantly impair kidney function and heighten the demand for advanced treatment and management strategies. Annually, about 1.3 million deaths are directly attributed to kidney disease, with an additional 1.4 million deaths resulting from cardiovascular complications linked to impaired kidney function. The alarming dual burden underscores the urgent need for innovative therapeutic interventions and robust preventive measures to mitigate the impact of CKD and its associated health risks, highlighting the critical focus on enhancing patient care and treatment outcomes globally.

The Chronic Kidney Disease market experiences increasing demand for pharmaceuticals addressing conditions like hypertension and diabetes, alongside advanced dialysis technologies. The Chronic Kidney Disease market growth is driven by the necessity for innovative therapies that effectively manage disease progression and enhance patient outcomes. The market increase is driven by rising healthcare expenditure, technological advancements in treatment methods, and favorable regulatory frameworks facilitating drug approvals and market entry.

Leading pharmaceutical firms, medical device manufacturers, and dialysis service providers dominate the supplier landscape, offering a wide array of treatment options. Profit margins within the Chronic Kidney Disease market vary by segment, with opportunities for growth in novel drug development, personalized medicine, and innovative dialysis solutions tailored to patient needs and healthcare efficiency.

To get more Insights: Request Free Sample Report

Chronic Kidney Disease Market Dynamics

The rising incidence of diabetes and hypertension

The Chronic Kidney Disease market is significantly influenced by the rising incidence of diabetes and hypertension, which are major risk factors for CKD. Diabetes, in particular, is a leading cause, with approximately 30 to 40% of individuals with diabetes developing CKD. Type 2 diabetes is the largest contributor to the CKD burden associated with diabetes. Kidney damage from diabetes results from hyperglycemia or related conditions such as hypertension, polyneuropathic bladder dysfunction, and infections. Individuals with diabetes-related kidney disease face higher risks of cardiovascular disease (CVD), progression to kidney failure, and mortality.

The global incidence of CKD due to type 2 diabetes increased from around 1.4 million new cases in 1990 to 2.8 million in 2019, marking a 74% rise. In 2018, the age-standardized incidence of diabetes-related CKD was 32.15% per 100,000. The upward trend in CKD among type 2 diabetes patients is observed across all economic regions and is inversely related to a country’s socio-demographic index. In contrast, a decline in CKD incidence has been noted among type 1 diabetes patients, underscoring the impact of the increasing prevalence of type 2 diabetes worldwide.

1. Hypertension affects approximately 1.28 billion adults aged 30-79 worldwide, with a significant proportion living in low- and middle-income countries.
2. About 46% of adults with hypertension are unaware of their condition, and less than half receive diagnosis and treatment. The lack of management contributes to the progression of Chronic Kidney Disease.
3. Only 21% of adults with hypertension have their blood pressure under control, increasing the risk of Chronic Kidney Disease development and complications.
4. A global target aims to reduce hypertension prevalence by 33% between 2010 and 2030, which, if achieved, is expected to mitigate its impact on Chronic Kidney Disease and related health outcomes.

Disparities in Healthcare

Socioeconomic and racial disparities significantly influence the Chronic Kidney Disease (CKD) market by affecting the diagnosis, treatment, and management of CKD. Marginalized communities often face barriers to accessing high-quality healthcare, resulting in delayed diagnosis, inadequate treatment, and poorer health outcomes. These disparities contribute to a higher burden of CKD and related complications in these populations, impacting the overall Chronic Kidney Disease market dynamics by creating a higher Chronic Kidney Disease market demand for healthcare resources and targeted interventions.

The CKD market responded to disparities in healthcare with focused initiatives such as increased demand for diagnostic services and outreach programs aimed at early CKD detection. Expansion of preventive and educational programs to manage diabetes and hypertension risks development of targeted therapies by pharmaceutical firms tailored to high-risk groups and policy and funding increases from governments and non-profits for CKD research and healthcare access improvements. These efforts aimed to address systemic issues contributing to CKD prevalence and enhance care quality in marginalized communities.

• According to SMR analysis, Hispanic and Native American populations also experienced higher rates of CKD, with limited access to nephrology care and preventive services exacerbating the issue.
• Quality of care for CKD patients varied significantly by race and socioeconomic status. Marginalized communities received less comprehensive care, impacting disease progression and outcomes. The higher prevalence of comorbid conditions like diabetes and hypertension in these populations further complicated CKD management.
• CKD awareness and treatment improved, but significant gaps remained in care quality for marginalized groups. These disparities continued to drive Chronic Kidney Disease market demand for targeted interventions and community health programs.

Chronic Kidney Disease Market Segment Analysis

By Treatment, Pharmaceutical interventions constitute a crucial component in managing Chronic Kidney Disease (CKD), focusing on mitigating disease progression, symptom management, and reducing associated complications such as cardiovascular disease. Drugs targeting hypertension, diabetes, and other primary causes of Chronic Kidney Disease are pivotal in controlling underlying conditions that exacerbate kidney function decline. The segment of the Chronic Kidney Disease market is characterized by a robust pipeline of research and development, continually introducing new therapies to address unmet medical needs and improve patient outcomes. Effective CKD drugs stabilize blood pressure, manage blood glucose levels, and reduce proteinuria, slowing kidney damage and lowering cardiovascular risk.

The rising global prevalence of diabetes, hypertension, and obesity propels demand for pharmaceutical treatments, driving Chronic Kidney Disease market growth. Technological advancements in drug delivery enhance efficacy and patient adherence. Increased healthcare expenditure, especially in developed regions, fuels investment in innovative CKD therapies, expanding the market. Stringent regulatory frameworks ensure drug safety and efficacy, shaping Chronic Kidney Disease market dynamics and adoption rates. These factors collectively influence the evolution and growth of the chronic kidney disease market.

Chronic Kidney Disease Market Regional Insights

North America is the dominant player in the global market, accounting for XX% of the Chronic Kidney Disease market share in 2023.  North America plays a pivotal role in the Chronic Kidney Disease market because of advanced healthcare infrastructure, the high prevalence of diabetes and hypertension, and significant investments in medical research and innovation. The region witnesses a substantial demand for CKD diagnostic services, advanced treatment options, and patient management solutions. The market in North America benefits from robust healthcare policies and reimbursement systems, which support comprehensive CKD care and access to advanced therapies.

In North America, pharmaceutical firms have prioritized developing novel CKD therapies targeting disease progression pathways. At the same time, advanced diagnostic technologies like biomarkers and imaging have been adopted, enhancing early detection and personalized treatment approaches. The COVID-19 pandemic further spurred telehealth expansion, facilitating broader access to nephrology consultations and remote monitoring for CKD patients, thereby advancing care delivery and patient outcomes in the region.

1. According to the analysis by SMR, chronic kidney disease (CKD) incurs higher costs in England compared to the combined costs of breast, lung, colon, and skin cancer treatments.
2. In the US, annual spending on chronic kidney disease (CKD) treatment is projected to surpass USD 48 billion, with Stage 5 programs alone accounting for 6.9% of the total Medicare budget, despite covering less than 1% of the insured population.
3. Approximately 15% of US adults, totaling around 37 million people, are estimated to be affected by chronic kidney disease (CKD).

Chronic Kidney Disease Market Competitive Landscape

1. In September 2023, AWAK Technologies secured over $20 million in Series B funding, marking a significant milestone in MedTech fundraising and among the largest in Southeast Asia. The round was co-led by Lion X Ventures, Vickers Venture Partners, Advanced MedTech, Eckuity Capital, and a major healthcare investment office. AWAK PD, their ultraportable peritoneal dialysis system, enables dialysis at home or on the go, addressing current challenges with stationary therapy.
2. In April 2023, Medtronic and DaVita jointly established Mozarc Medical, focusing on renal care technologies for at-home treatments. Both companies equally invested $200 million to launch the venture. Mozarc will advance dialysis delivery systems and kidney disease treatments, combining DaVita's dialysis expertise with Medtronic's medical device capabilities.
3. November 2023: Sun Pharma collaborates with Zydus Lifesciences to co-market a drug for Chronic Kidney Disease (CKD), while Bayer introduces a pill for CKD associated with diabetes.
4. October 2023: Medtronic initiates a clinical trial to assess the safety and effectiveness of its new renal denervation catheter for CKD treatment, as AstraZeneca's Farxiga gains US approval for CKD therapy.
5. September 2023: Fresenius Medical Care earns FDA breakthrough device designation for its latest hemodialysis machine, and Boehringer Ingelheim and Eli Lilly commence clinical trials for their oral SGLT2 inhibitor for CKD.
6. August 2023: Novartis launches a global initiative to enhance CKD awareness and access to care, while DaVita Kidney Care partners with Verily to develop new digital health tools for CKD patients.

Key Player in the Chronic Kidney Disease Market  

1. Sanofi
2. AstraZeneca plc.
3. Amgen Inc.
4. Regeneron Pharmaceuticals, Inc.
5. AbbVie Inc.
6. ProKidney Corp.
7. Pfizer, Inc.
8. Bayer AG, F. Hoffmann-La Roche AG
9. Kissei Pharmaceutical Co.
10. Reata Pharmaceuticals
11. GlaxoSmithKline plc.
12. Ardelyx Inc.
13. Boehringer Ingelheim International GmbH
14. Novo Nordisk
15. Novartis AG
16. Johnson & Johnson
17. Astellas Pharma Inc.
18. Takeda Pharmaceutical Company Limited
19. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
20. Kibow Biotech, Inc.
21. FibroGen, Inc.
22. Cara Therapeutics
23. Pieris Pharmaceuticals, Inc.
24. Mitsubishi
25. OPKO Health
26. XXX Inc.